Manner Hendrik, Rabenstein Thomas, May Andrea, Pech Oliver, Gossner Liebwin, Werk Daniel, Manner Nicola, Günter Erwin, Pohl Jürgen, Vieth Michael, Stolte Manfred, Ell Christian
Department of Internal Medicine II, Dr. Horst-Schmidt-Kliniken, Teaching Hospital of the University of Mainz, Wiesbaden, Germany.
Am J Gastroenterol. 2009 Mar;104(3):566-73. doi: 10.1038/ajg.2008.151. Epub 2009 Feb 17.
In the West, neither acute nor long-term results of endoscopic resection (ER) for early gastric cancer (EGC) have been reported in large studies. The aim of this study was to prospectively evaluate the efficacy and safety of ER in patients with EGC in a long-term follow-up (FU).
From May 1995 to October 2004, 179 patients were referred to our department for endoscopic therapy (ET) of gastric cancer (GC). Of these, 43 patients had intramucosal GC with a diameter of up to 30 mm and underwent ER with curative intent. All patients underwent a strict FU protocol at regular intervals.
Of the 43 patients, 42 fulfilled our low-risk criteria for ET of EGC: gross tumor type I/II, intramucosal GC, diameter up to 30 mm, tumor differentiation G1/G2, and no infiltration into lymph vessels/veins. Two patients were not available for FU (remission status not evaluated). In another patient, gastric mucosa-associated lymphoid tissue lymphoma was detected simultaneously, and he was referred for surgery. 38 (97%) of the remaining 39 patients who underwent definitive ET (23 males (59%); mean age 69+/-10 years) achieved complete remission (CR) after a mean of 1.3+/-0.6 ER sessions. Minor complications (not Hb-relevant bleeding) occurred in 7 of the 39 patients (18%) and major complications (5 Hb-relevant bleeds, 1 covered perforation; all managed conservatively) in 6 patients (15%). During FUs (mean 57 months; range 5-137), recurrent or metachronous lesions were observed in 11 patients (29%). All lesions were successfully treated by repeated ET. No tumor-related deaths occurred during FU.
Although ER for EGC in Western countries is effective, it is associated with a relevant risk of complications. In view of the possibility of recurrent or metachronous neoplasia, a strict FU protocol is mandatory.
在西方,尚未有大型研究报道早期胃癌(EGC)内镜切除(ER)的急性或长期结果。本研究的目的是对EGC患者进行长期随访,前瞻性评估ER的疗效和安全性。
1995年5月至2004年10月,179例患者因胃癌(GC)的内镜治疗(ET)转诊至我科。其中,43例患者为直径达30mm的黏膜内GC,接受了旨在治愈的ER。所有患者定期接受严格的随访方案。
43例患者中,42例符合我们EGC的ET低风险标准:大体肿瘤类型I/II、黏膜内GC、直径达30mm、肿瘤分化G1/G2且无淋巴管/静脉浸润。2例患者无法进行随访(未评估缓解状态)。另1例患者同时检测出胃黏膜相关淋巴组织淋巴瘤,已转诊接受手术。其余39例接受确定性ET的患者中(23例男性(59%);平均年龄69±10岁),38例(97%)在平均1.3±0.6次ER治疗后实现完全缓解(CR)。39例患者中有7例(18%)发生轻微并发症(与血红蛋白无关的出血),6例患者(15%)发生严重并发症(5例与血红蛋白相关的出血,1例覆膜穿孔;均保守处理)。在随访期间(平均57个月;范围5 - 137个月),11例患者(29%)观察到复发或异时性病变。所有病变均通过重复ET成功治疗。随访期间未发生与肿瘤相关的死亡。
尽管西方国家EGC的ER有效,但它与相关并发症风险相关。鉴于复发或异时性肿瘤形成的可能性,严格的随访方案是必不可少的。